Specialty Enzymes & Probiotics hired Assad Al-Ammar, PhD, as Director of its analytical laboratory. Al-Ammar brings more than 25 years of experience as laboratory manager at Kansas Laboratories and Irvine Pharmaceutical, and as analytical methods development chemist for EXOVA, Santa Fe Springs and Natural Alternative International. Al-Ammar has published 35 peer-reviewed research papers for analytical journals in the United States and Europe.
Al-Ammar earned his Ph.D. from Glasgow University, and a post-doctorate in analytical chemistry from the University of Massachusetts. Additionally, he has experience in classical and new analytical techniques such as gravimetric, volumetric, electrochemical, ICP-OES, ICP-MS, GC-MS-MS, LC-MS-MS and HPLC.
He will lead Specialty Enzymes & Probiotics as it continues to grow and expand as an analytical contract laboratory with an expertise in enzyme and probiotic assays, identity, viscosity and microbiological testing, as well as ICP-OES heavy metals and other metal testing.
The company also hired Thomas Laaman, PhD, as director of technical sales. Laaman has led research and sales teams at companies such as Merck, Bio-Cat, FMC Corporation, Pepsico, and Kimica. He brings basic and applied scientific knowledge with degrees from Cornell, Ohio State, Texas A&M, and a post-doctoral stint at the University of Texas Medical School.
Laaman is passionate about sharing the ways probiotics and enzymes can promote optimal human health with nutraceutical companies. He joined Specialty Enzymes & Probiotics at this time, he says, because the company has been a long-time true manufacturer of enzymes and probiotics, and will continue to be at the cutting edge of conceiving, testing and manufacturing advanced solutions to naturally support well-being. Laaman says, “We offer 18+ probiotic species, and have a technical sales team that can not only explain the subtleties of each of them, but also establish a nuanced understanding for why specific blends will provide maximum health benefits.”
New shelter data casts doubt on whether the pet population and pet ownership are truly growing.
While the pandemic caused unprecedented suffering worldwide in 2020, the disruptions to dogs, cats and other pets adoption numbers may normalize in 2021.